<?xml version="1.0" encoding="UTF-8"?>
<p>SOC systemic treatment regimen is determined by the treating clinician and will be declared upfront prior to randomisation. The decision as to which SOC systemic treatment is initiated should be made with reference to the current National Institute for Health and Care Excellence (NICE) and regional National Health Service (NHS) clinically commissioned guidelines.
 <xref rid="R59" ref-type="bibr">59</xref> At present, docetaxel is recommended for use in all men with newly diagnosed metastatic prostate cancer who do not have significant comorbidities.
 <xref rid="R59" ref-type="bibr">59 60</xref> Alternatively, new anti-androgen compounds, including but not limited to, abiraterone acetate or enzalutamide, are permitted if approved by regional NHS clinically commissioned guidelines.
 <xref rid="R59" ref-type="bibr">59 61</xref>
</p>
